Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MSH2 |
Variant | loss |
Impact List | unknown |
Protein Effect | loss of function |
Gene Variant Descriptions | MSH2 loss indicates loss of the MSH2 gene, mRNA, and protein. |
Associated Drug Resistance | |
Category Variants Paths |
MSH2 mutant MSH2 inact mut MSH2 loss |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MSH2 loss | colorectal cancer | sensitive | Cytarabine | Preclinical | Actionable | In a preclinical study, colorectal cancer cells deficient in MSH2 had increased sensitivity to Cytosar-U (cytarabine) in culture (PMID: 23361057). | 23361057 |
MSH2 loss | endometrial carcinoma | not applicable | N/A | Preclinical | Emerging | Preclinical shRNA mediated-inhibition of POLB in human endometrial carcinoma cells with MSH2 loss resulted in synthetic lethality, suggesting POLB may be a promising therapeutic target for MSH2 deficient cancer cells (PMID: 20227038). | 20227038 |